Virus-like particles as vaccines for paramyxovirus
AssigneeUniversity of Massachusetts
InventorTrudy Morrison
Life of this patent
Estimating the term…
Abstract
The invention provides expression vectors and virus-like particles (VLPs) containing Newcastle Disease Virus Sequences in combination with sequences encoding proteins of interest. The vectors are useful in, for example, generating virus-like particles (VLPs) that contain proteins of interest. In one embodiment, the expressed VLPs elicit an immune response by an animal host against the protein. The invention's VLPs are useful as, for example, vaccines.
Claims56
A virus-like particle (VLP) comprising
- a) Newcastle disease virus matrix (M) protein,
- b) Newcastle Disease Virus heamagglutinin-neuraminidase (HN) protein transmembrane domain (TM) protein,
- c) Newcastle Disease Virus heamagglutinin-neuraminidase (HN) protein cytoplasmic domain (CT) protein, and
- d) Respiratory Syncytial Virus (RSV) ectodomain protein,
- wherein said transmembrane (TM) protein is flanked by said cytoplasmic domain (CT) protein and said ectodomain protein.
A method for producing a Respiratory Syncytial Virus (RSV) ectodomain protein, comprising
- a) providing an expression vector comprising, in operable combination,
- 1) a first nucleic acid sequence encoding a Newcastle disease virus HN transmembrane domain (TM) protein,
- 2) a second nucleic acid sequence encoding Newcastle disease virus HN cytoplasmic domain (CT) protein,
- 3) a third nucleic acid sequence encoding a Respiratory Syncytial Virus (RSV) ectodomain protein, wherein said first nucleic acid sequence is flanked by said second and third nucleic acid sequences, and
- 4) a fourth nucleic acid sequence encoding Newcastle Disease Virus matrix (M) protein,
- b) providing a target host cell, and
- c) transfecting said target host cell with said vector to produce a transfected host cell that produces virus-like particles (VLPs) that comprise said RSV ectodomain protein.
A VLP produced by a method comprising
- a) providing an expression vector comprising, in operable combination,
- 1) a first nucleic acid sequence encoding Newcastle Disease Virus heamagglutinin-neuraminidase (HN) protein transmembrane domain (TM) protein,
- 2) a second nucleic acid sequence encoding Newcastle Disease Virus heamagglutinin-neuraminidase (HN) protein cytoplasmic domain (CT) protein,
- 3) a third nucleic acid sequence encoding Respiratory Syncytial Virus (RSV) ectodomain protein, wherein said first nucleic acid sequence is flanked by said second and third nucleic acid sequences, and
- 4) a fourth nucleic acid sequence encoding Newcastle Disease Virus matrix (M) protein,
- b) providing a target host cell, and
- c) transfecting said target host cell with said vector to produce a transfected host cell that produces virus-like particles (VLPs) that comprise said RSV ectodomain protein.
A method for producing a Respiratory Syncytial Virus (RSV) ectodomain protein, comprising
- a) providing a first expression vector comprising, in operable combination,
- 1) a first nucleic acid sequence encoding Newcastle disease virus heamagglutinin-neuraminidase (HN) protein transmembrane domain (TM) protein,
- 2) a second nucleic acid sequence encoding Newcastle Disease Virus heamagglutinin-neuraminidase (HN) protein cytoplasmic domain (CT) protein, and
- 3) a third nucleic acid sequence encoding a Respiratory Syncytial Virus (RSV) ectodomain protein, wherein said first nucleic acid sequence is flanked by said second and third nucleic acid sequences,
- b) providing a second expression vector comprising a fourth nucleic acid sequence encoding Newcastle Disease Virus matrix (M) protein,
- c) providing a target host cell, and
- d) transfecting said target host cell with said first and second vectors to produce a transfected host cell that produces virus-like particles (VLPs) that comprise said RSV ectodomain protein.
Dependencies are inferred from the claim text.